Finance

Lists
Why is CSPCY down 4,32%?
Dive Deeper
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
4,81 $
-4,32%
(-0,22) 1D
8 қаз., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSPCY...
Open
4,81 $
High
4,81 $
Low
4,81 $
Mkt. cap
105,43 млрд
Avg. vol.
1,61 мың
Volume
278,00
52-wk high
5,46 $
52-wk low
3,26 $
Beta
0,37
Shares outstanding
2,88 млрд
No. of employees
19 мың
Open
4,81 $
High
4,81 $
Low
4,81 $
Mkt. cap
105,43 млрд
Avg. vol.
1,61 мың
Volume
278,00
52-wk high
5,46 $
52-wk low
3,26 $
Beta
0,37
Shares outstanding
2,88 млрд
No. of employees
19 мың
News stories
From web sources and news partners
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceuticals Group ADR
CEOZhang Cuilong
Employees18,6 мың
Founded1992
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
6,62 млрд
6,11 млрд
6,47 млрд
12,13 млрд
Cost of goods sold
2,28 млрд
2,11 млрд
2,20 млрд
2,24 млрд
Cost of revenue
2,28 млрд
2,11 млрд
2,20 млрд
2,24 млрд
Research and development expenses
1,50 млрд
1,62 млрд
1,40 млрд
1,63 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,97 млрд
1,87 млрд
1,89 млрд
1,89 млрд
Operating expense
3,47 млрд
3,49 млрд
3,29 млрд
3,51 млрд
Total operating expenses
5,75 млрд
5,60 млрд
5,49 млрд
5,75 млрд
Operating income
869,63 млн
514,71 млн
973,82 млн
6,38 млрд
Other non operating income
645,14 млн
-470,42 млн
181,80 млн
11,92 млн
EBT including unusual items
1,18 млрд
505,59 млн
1,13 млрд
6,40 млрд
EBT excluding unusual items
1,37 млрд
186,56 млн
1,13 млрд
6,35 млрд
Income tax expense
222,47 млн
165,64 млн
243,25 млн
825,70 млн
Effective tax rate
18,78%
32,76%
21,46%
12,91%
Other operating expenses
-
-
-
-
Net income
963,54 млн
370,72 млн
859,79 млн
5,23 млрд
Net profit margin
14,56%
6,06%
13,30%
43,16%
Earnings per share
-
-
-
-
Interest and investment income
-
195,87 млн
-
91,68 млн
Interest expense
-104,94 млн
-6,76 млн
-11,01 млн
-2,30 млн
Net interest expenses
-104,94 млн
189,12 млн
-11,01 млн
89,37 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,14 млрд
802,06 млн
1,26 млрд
6,67 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары